PRKAR2B

Across TCGA pan-cancer cohorts, PRKAR2B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRKAR2B data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PRKAR2B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PRKAR2B expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, UCEC, and HNSC are the cancer types where PRKAR2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.545	0.283	.001	51	view →
UCEC	DFS	Tertile	II,III,IV	0.546	1.000	.020	12	view →
HNSC	OS	Median	All	1.000	0.484	.038	12	view →
CCRCC	OS	Median	IV	1.000	0.202	.034	8	view →
LUAD	DFS	Tertile	III,IV	0.312	0.720	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PRKAR2B–PDAC (DFS)

Open the PDAC breakdown →